



(43) International Publication Date
21 March 2013 (21.03.2013)

(10) International Publication Number
WO 2013/037960 A1

(51) International Patent Classification:

C07D 209/08 (2006.01) *A61K 31/404* (2006.01)
C07D 235/06 (2006.01) *C07D 265/16* (2006.01)
C07D 471/04 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/EP2012/068101

(22) International Filing Date:

14 September 2012 (14.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11382296.9 16 September 2011 (16.09.2011) EP

(71) Applicants (for all designated States except US):

LABORATORIOS DEL DR. ESTEVE, S.A. [ES/ES];
Avda. Mare de Deu de Montserrat, 221, E-08041 Bar-
celona (ES). **DRACONIS PHARMA, S.L.** [ES/ES]; C/
Innovació, 2, E-08225 TERRASSA (Barcelona) (ES).
ALMIRALL, S.A. [ES/ES]; Ronda del General Mitre,
151, E-08022 Barcelona (ES). **TORRENS JOVER,**
Andoni [ES/ES]; Carrer del Racó, 8 2º 2ª, E-08221 TER-
RASSA (Barcelona) (ES).

(72) Inventor; and

(71) Applicant : **CARCELLER GONZÁLEZ, Elena**
[ES/ES]; C/Joan Miró 2, 2º 1º, E-08173 SANT CUGAT
DEL VALLÈS (Barcelona) (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MERCÈ VIDAL,**
Ramon [ES/ES]; c/ Casanova, 264 - 4º 1ª, E-08021 Bar-
celona (ES). **CALDENTY FRONTERA, Francesc**

Xavier [ES/ES]; C/ Caputxins, 21 bis 4º 1ª, E-43001 Tar-
ragona (ES). **RODRÍGUEZ GARRIDO, Antonio, David**
[ES/ES]; Rúa Castelao, 17, E-36980 O Grove (pontevedra)
(ES). **SALAS SOLANA, Jordi** [ES/ES]; C/ Juli González
nº 2 3º 1º, E-08401 GRANOLLERS (Barcelona) (ES).

(74) Agent: **CARPINTERO LOPEZ, Francisco**; Herrero &
Asociados, S.L., C/ Alcalá, 35, E-28014 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: EP1 RECEPTOR LIGANDS

(57) Abstract: The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of gener-
al formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation,
to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to
pharmaceutical compositions comprising them.



WO 2013/037960 A1